Osteoarthritis
Conditions
Brief summary
This study will prospectively compare compliance rates between a novel FDA cleared wearable compression therapy with and without digital engagement for DVT prophylaxis in both hospital and home environments after total knee or hip arthroplasty.
Detailed description
This study is a single-arm, open-label, prospective, single-center study designed to evaluate compliance to CirvoTM therapy use with and without digital engagement. Historical questionnaire data with a different compression device will be compared to the same questionnaire used for the prospective cohort of up to 200 subjects. All patients prescribed compression therapy following total joint arthroscopy will be offered participation. Subjects will receive CirvoTM compression therapy according to the standard of care protocol at NYU during or after surgery and 18 hours per day for 14 days. 1. Baseline: Following consent, participants will provide demographic, medical history and information with respect to their elective orthopedic procedure and receive training on the CirvoTM device. Participants will be randomized to either digital engagement or no digital engagement groups. 2. Post procedure: After the procedure, CirvoTM device operation will be reviewed with the participant. 3. Discharge: Any adverse events occurring during hospitalization will be reviewed, data capture on the CirvoTM app will be confirmed. 4. 14- day visit: Participants will complete a patient satisfaction questionnaire, provide information with respect to any adverse events including specific details about DVT and readmission and return the devices. 5. 30-day phone call/visit: Participants will be contacted at 30 days to answer questions about DVT's and readmissions.
Interventions
OTHERChange in User interfaces of Cirvo compression device application.
Comparison of 2 versions of the Circo user interface
OTHERChange in Satisfaction in use of Cirvo device
Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
Sponsors
NYU Langone Health
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Male or female over the age of 18 * Undergoing elective primary total hip/knee replacement * Planned discharge to home * Able to train to and operate the Cirvo device with app
Exclusion criteria
* History of Pulmonary Embolism * Active cancer * BMI \>40 * Current smoker * History of a hyper-coaguable condition * Actual or expected prolonged bedrest for \>3 days * Calf geometry on which Cirvo device does not appropriately fit (prospective cohort only) * Known sensitivity to any of the materials used in the Cirvo device (prospective cohort only) * Currently participating or planning to participate in any other investigational clinical evaluation during study period that may, in the opinion of the investigator, affect compliance (prospective cohort only)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in compliance using Cirvo compression therapy | 14 day visit (+7 days) | A sample size of 100 subjects is powered at 90% to show a difference of 10% in compliance between the 2 digital engagement cohorts. For each subject, Compliance will be calculated for each participant during the course of therapy in terms of the number of hours of actual use/number of hours of prescribed use. The number of hours will be summarized as days of use for each group. The means of each group will be presented. The primary endpoint is the difference in compliance between the group assigned to digital engagement versus no digital engagement with the Cirvo app. The mean difference will be compared to zero using the paired t-test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in patient satisfaction using Cirvo compression therapy | 14 day visit (+7 days) | A comparison between the satisfaction of CirvoTM therapy versus the historical data from comparator device use will be performed. Results of the usability questionnaire (Patient Satisfaction Intermittent Compression Devices Questionnaire) will be qualitatively summarized. |
| Change in staff satisfaction using Cirvo compression therapy. | 14 day visit (+7 days) | A comparison between the satisfaction of CirvoTM therapy versus the historical data from comparator device use will be performed. Results of the usability questionnaire will be qualitatively summarized. Staff Satisfaction Intermittent Compression Devices Questionnaire will be administered. |
| Change in patients satisfaction using Cirvo compression therapy | 30 day visit | A comparison between the satisfaction of CirvoTM therapy versus the historical data from comparator device use will be performed. Results of the usability questionnaire (Patient Satisfaction Intermittent Compression Devices Questionnaire) will be qualitatively summarized. |
Outcome results
None listed